# Dingwei Ye

Source: https://onco.cc/people/ye-dingwei/  
OnCo record `ye-dingwei` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dingwei Ye is China's leading uro-oncologist, whose department runs the Chinese arms of major prostate and bladder cancer trials.

## Summary

Dingwei Ye is Professor and Chair of the Department of Urology at Fudan University Shanghai Cancer Center. He is China's leading uro-oncologist, and his department runs the Chinese arms of major prostate and bladder cancer trials, including studies of androgen receptor pathway inhibitors such as enzalutamide, PARP inhibitors, and the antibody-drug conjugates enfortumab vedotin and disitamab vedotin in urothelial cancer. His publications include trials of abiraterone plus prednisone and of apalutamide in metastatic castration-sensitive prostate cancer, including the LATITUDE study. His interests span prostate, bladder and kidney cancer and urologic surgery.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor and Chair, Department of Urology, Fudan University Shanghai Cancer Center
- Specialisms: Prostate cancer; Bladder cancer; Kidney cancer; Urologic surgery

## Sources

- Fudan University Shanghai Cancer Center: https://www.shca.org.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- institutions: [Fudan University Shanghai Cancer Center](https://onco.cc/institutions/fuscc/)

---
JSON: https://onco.cc/api/v1/entities/ye-dingwei.json